SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Considerations for CTO Stenting


Stent overexpansion capabilities are critical for CTO lesions which tend to be long and in large vessels.

The SYNERGY Stent is indicated for treatment of patients presenting with coronary artery total occlusion lesions and has a labeled overexpansion of up to 5.75mm allowing the physician to customize the stent to the appropriate vessel size.
SYNERGY Stent System DFU

Stent mechanical properties are important considerations for CTO stenting.

The SYNERGY Stent’s customized architecture offers exceptional strength and conformability. 

Radial Strength1

Radial Strength: Amount of radial force required to reduce the diameter of a deployed stent by 15%

Conformability1

SYNERGY Conformability Chart
Conformability: The amount of torque required to bend the stent to a specific curvature

Chronic Total Occlusion PCI and Vessel Healing

The SYNERGY Stent’s bioabsorbable polymer and abluminal coating are designed for early healing as the polymer is gone when no longer needed, shortly after completion of drug elution at 3 months.
SYNERGY Stent Drug and Polymer Elution
Wilson, G.J., et al. Catheter Cardiovasc Interv. 2015.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

Boston Scientific is committed to supporting studies evaluating the SYNERGY Stent in patient populations that interventional Cardiologists see in their everyday practice, including CTO stenting.
Top